DUBLIN--(BUSINESS WIRE)--The "Global Pneumonia Market: Industry Analysis & Outlook (2018-2025)" report has been added to ResearchAndMarkets.com's offering.
Global Pneumonia Market: Industry Analysis & Outlook (2018-2025) provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering U.S. and Europe along with the global market. The report profiles key players of the market including Merck & Co. Inc., Allergan Plc, The Medicines Company and Nabriva Therapeutics.
The U.S. is expected to be the first region to start selling pneumonia drugs in pipeline and later on, penetration of pneumonia drugs would occur in Europe. The U.S. and Europe have high prevalence of severe forms of multiple drug resistance (MDR) organism which would result into a high demand for pneumonia drugs in future.
The global pneumonia market is expected to grow in future with growing aging population, increasing pharmaceutical R&D spending, increasing healthcare expenditure, accelerating economic growth, growing children population and rise in multiple drug resistance (MDR) organisms. Key trends of this market include progressing drug under pipeline, innovation in treatment options and increased preference towards combination therapy. However, there are some factors which can hinder growth of the market including stringent regulations and entry of generic drugs.
- Growing Aging Population
- Increasing Pharmaceutical R&D Spending
- Increasing Healthcare Expenditure
- Accelerating Economic Growth
- Growing Children Population
- Rise in Multiple Drug Resistance (MDR) Organisms
Key Trends & Developments
- Progressing Drugs Under Pipeline
- Innovation in Treatment Methods
- Increased Preference Towards Combination Therapy
- Stringent Regulations
- Entry of Generic Drugs
Key Topics Covered:
1. Market Overview
2. Global Pneumonia Market Analysis
3. Regional Markets
4. Market Dynamics
5. Competitive Landscape
6. Company Profiles
- Allergan Plc
- Merck & Co., Inc.
- Nabriva Therapeutics
- The Medicines Company
For more information about this report visit https://www.researchandmarkets.com/research/3lj8dj/global_pneumonia?w=4